MDPI and ACS Style
Kim, J.H.; Yoo, C.; Seo, S.; Jeong, J.H.; Ryoo, B.-Y.; Kim, K.-p.; Lee, J.B.; Lee, K.-W.; Kim, J.-W.; Kim, I.-H.;
et al. A Phase II Study to Compare the Safety and Efficacy of Direct Oral Anticoagulants versus Subcutaneous Dalteparin for Cancer-Associated Venous Thromboembolism in Patients with Advanced Upper Gastrointestinal, Hepatobiliary and Pancreatic Cancer: PRIORITY. Cancers 2022, 14, 559.
https://doi.org/10.3390/cancers14030559
AMA Style
Kim JH, Yoo C, Seo S, Jeong JH, Ryoo B-Y, Kim K-p, Lee JB, Lee K-W, Kim J-W, Kim I-H,
et al. A Phase II Study to Compare the Safety and Efficacy of Direct Oral Anticoagulants versus Subcutaneous Dalteparin for Cancer-Associated Venous Thromboembolism in Patients with Advanced Upper Gastrointestinal, Hepatobiliary and Pancreatic Cancer: PRIORITY. Cancers. 2022; 14(3):559.
https://doi.org/10.3390/cancers14030559
Chicago/Turabian Style
Kim, Jwa Hoon, Changhoon Yoo, Seyoung Seo, Jae Ho Jeong, Baek-Yeol Ryoo, Kyu-pyo Kim, Jung Bok Lee, Keun-Wook Lee, Ji-Won Kim, Il-Hwan Kim,
and et al. 2022. "A Phase II Study to Compare the Safety and Efficacy of Direct Oral Anticoagulants versus Subcutaneous Dalteparin for Cancer-Associated Venous Thromboembolism in Patients with Advanced Upper Gastrointestinal, Hepatobiliary and Pancreatic Cancer: PRIORITY" Cancers 14, no. 3: 559.
https://doi.org/10.3390/cancers14030559